Stergiopoulou et al. reported a long-term follow-up of 13 breast cancer patients who received comprehensive CTC monitoring, including measurements of EpCAM, phenotypic analysis, CSC marker analysis, PIK3CA and ESR1 mutations, and ESR1 methylation. Here, ESR1 is linked to breast carcinoma.